Clinical Trials Directory

Trials / Completed

CompletedNCT05047692

Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers

A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Cellid Co., Ltd. · Industry
Sex
All
Age
19 Years – 64 Years
Healthy volunteers
Accepted

Summary

This is a Phase 1 clinical trial to assess the safety and immunogenicity of AdCLD-CoV19-1 in healthy adults.

Detailed description

This is a dose-escalation, multi-center, open-label, Phase 1 clinical trial. We assess the safety of AdCLD-CoV19-1 and immune responses against SARS-CoV-2. DSMB will evaluate safety when events occurred during the whole study period.

Conditions

Interventions

TypeNameDescription
BIOLOGICALAdCLD-CoV19-1Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein

Timeline

Start date
2021-09-09
Primary completion
2022-12-02
Completion
2023-06-21
First posted
2021-09-17
Last updated
2023-07-28

Locations

3 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT05047692. Inclusion in this directory is not an endorsement.